Skip to main content
Premium Trial:

Request an Annual Quote

OncoDNA Acquires Spanish Cancer Genomics Firm BioSequence

NEW YORK (GenomeWeb) – OncoDNA announced today that it has acquired Spanish personalized cancer genomics firm BioSequence as part of an effort to expand its presence in Europe.

The transaction comes about two years after Belgium-based OncoDNA signed an agreement with BioSequence making it the exclusive Spanish distributor of OncoDNA’s clinical oncology molecular diagnostics such as OncoDeep Dx, which uses next-generation sequencing, fluorescence in situ hybridization, immunohistochemistry, and other approaches to analyze solid tumors.

"This acquisition is part of OncoDNA's strategy for growth, linked with our recent capital increase," OncoDNA Founder and CEO Jean-Pol Detiffe said in a statement. "We are well aware of the BioSequence team's abilities and professionalism, and we have complete confidence in its potential."

Specific terms of the acquisition were not disclosed. OncoDNA said that it would work closely with BioSequence to transition its expertise in the Spanish market, and that it would extend its operations to include Portugal and Latin America.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.